As described above, even though GAD antibodies were negative (Table 1), the inappropriately low C-peptide levels and sudden onset and persistent hyperglycemia with a presentation of DKA confirmed immune-related T1DM induced by nivolumab therapy as DIRE. The gene discussed is GAD1; the disease is type 1 diabetes mellitus.